Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial
Ildiko Lingvay(Southwestern Medical Center), Andrei‐Mircea Catarig(Novo Nordisk (Denmark)), Juan P. Frías(National Research Institute), Harish Kumar(Amrita Institute of Medical Sciences and Research Centre), Nanna L. Lausvig(Novo Nordisk (Denmark)), Carel W. le Roux(University College Dublin), Desirée Thielke(Novo Nordisk (Denmark)), Adie Viljoen, Rory J. McCrimmon(University of Dundee)
Cited by 283Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis